Assoc Prof Dr. Mario I. Vega – Tumor Immunology – Best Researcher Award

Posted on by Pencis

 

Assoc Prof Dr. Mario I. Vega - Tumor Immunology - Best Researcher Award

University of California Los Angeles - United States

Author Profile

Orcid

EARLY ACADEMIC PURSUITS:

Mario I. Vega initiated his academic journey at the Universidad Autónoma Metropolitana Campus Xochimilco, Mexico City, serving as a Research Technical Assistant in the Department of Leptospirosis Human Research from 1991 to 1992. He continued his research roles at the Hospital Infantil de Mexico "Federico Gomez" and the Instituto Mexicano del Seguro Social (IMSS) with a focus on immunology and infectious diseases.

PROFESSIONAL ENDEAVORS:

Mario I. Vega's professional trajectory includes positions at prestigious institutions, such as UCLA AIDS Institute and IMSS, where he advanced from Assistant Researcher to Professor in the field of tumor immunology and infectious diseases. Notably, he has been associated with UCLA Medical Center, Jonsson Comprehensive Cancer Center, contributing as Staff Associate Researcher in the Clinical Nutrition Division.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY:

Dr. Vega's research contributions span diverse areas, from rituximab inhibition of p38 MAPK activity in B NHL to extensive work in immunology, cancer, and infectious diseases. His research expertise includes molecular biology, DNA replication, PCR, and immunotherapy. Serving on various review committees and editorial boards, he has actively contributed to scientific evaluations and publications.

IMPACT AND INFLUENCE:

Dr. Mario I. Vega's impact is evident through numerous honors and awards, such as the American Society of Hematology (ASH) Travel Award in 2004 and consecutive Fogarty fellowships at UCLA from 2004 to 2013. His recognition extends to national and international awards in pediatric research, biomedical research, and contributions to scientific journals.

ACADEMIC CITES:

Dr. Vega has left a mark on academia with memberships in esteemed organizations like ASH, AACR, and AAI. His participation in teaching activities, including courses on molecular biology, immunology, and cancer, demonstrates his commitment to knowledge dissemination.

LEGACY AND FUTURE CONTRIBUTIONS:

This overview highlights Dr. Mario I. Vega's academic and professional journey, his substantial contributions to medical research, and the potential impact of his continued work on the fields of immunology and oncology.

Notable Publications

Regulation of Krüppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma.2019 

Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.2022

Roles and Regulation of BCL-xL in Hematological Malignancies.2022

 

 

Prof Dr.Isabel Heidegger – Oncology and Precision Medicine – Best Researcher Award

Posted on by Pencis

Prof Dr.Isabel Heidegger - Oncology and Precision Medicine - Best Researcher Award

Medizinische Universität Innsbruck - Austria

AUTHOR PROILE

Scopus

EARLY ACADEMIC PURSUITS:

Isabel Heidegger commenced her academic journey with a strong foundation in the field of medicine. She pursued her early education with a focus on urology, setting the stage for her future contributions to the medical community.

PROFESSIONAL ENDEAVORS:

Isabel Heidegger's professional journey has been marked by significant achievements. Joining the Department of Urology at the Medical University Innsbruck in 1984, she steadily progressed in her career. Currently holding the distinguished position of Professor of Translational Prostate Cancer Therapy and Deputy Director of the Department of Urology, her leadership is evident in both clinical and research aspects.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Heidegger has made substantial contributions to the field of oncology and precision medicine, with a primary focus on translational prostate cancer therapy. Her work encompasses both basic-translational and clinical science. Her dedication to prostate cancer research extends to conservative and surgical treatment modalities.

IMPACT AND INFLUENCE:

As a physician-scientist specializing in prostate cancer, Heidegger's impact reverberates through her extensive research and clinical endeavors. Her commitment to advancing knowledge and improving patient outcomes has positioned her as a key influencer in the domain of urology.

ACADEMIC CITES:

Isabel Heidegger's work has garnered recognition in academic circles, evident in her citations and contributions to scholarly publications. Her research findings and clinical insights have contributed to the academic discourse in urology and prostate cancer treatment.

LEGACY AND FUTURE CONTRIBUTIONS:

Heidegger's legacy is shaped by her tireless pursuit of excellence in prostate cancer research and therapy. Her ongoing contributions lay the groundwork for future advancements in urology. The impact of her work is poised to endure, leaving a lasting legacy in the realm of translational medicine and prostate cancer treatment.

NOTABLE PUBLICATION

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.2023

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.2022

 

 

-

Mr.Manoj Kumar Srinivasan – Cancer Cell Biology – Best Researcher Award

Posted on by Pencis

Mr.Manoj Kumar Srinivasan - Cancer Cell Biology - Best Researcher Award

Annamalai University - Chidambaram

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Manojkumar Srinivasan embarked on his academic journey with a Master of Science in Biotechnology at Annamalai University, India, from July 2016 to May 2021. His commitment and dedication during this period were reflected in his impressive Cumulative Grade Point (CGP) of 80.03%. As part of his academic pursuits, he also pursued a Diploma in Food and Nutrition from June 2020 to May 2021, further diversifying his expertise.

PROFESSIONAL ENDEAVORS

In March 2022, Manojkumar stepped into the realm of research as a Project Fellow in the Cancer Biology Lab at the Department of Biochemistry & Biotechnology, Annamalai University, India. In this role, he is actively engaged in a project titled "Synthesis of pH-sensitive Carvacrol Zinc Oxide Quantum Dots (CVC-ZnO QDs) and evaluation of its anti-neoplastic and antimetastatic effect in vitro and in vivo." This experience has allowed him to apply his academic knowledge to real-world scientific investigations.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER CELL BIOLOGY

Manojkumar's Master's thesis, conducted at the Department of Biotechnology, Annamalai University, focused on the "Proximate analysis and glycemic index of Manipuri black rice." This research not only showcased his analytical skills but also contributed valuable insights to the understanding of nutritional aspects of Manipuri black rice.

IMPACT AND INFLUENCE

While pursuing his Ph.D. in Biotechnology at Annamalai University since January 2022, Manojkumar has been immersed in research endeavors, demonstrating his commitment to advancing knowledge in the field. His work in cancer cell biology, particularly in the synthesis and evaluation of novel quantum dots, holds promise for potential applications in anti-neoplastic and antimetastatic interventions.

ACADEMIC CITATIONS

Manojkumar's academic journey is marked by rigorous exploration and study, laying the foundation for his contributions to the scientific community. His work may have garnered citations and acknowledgments within academic circles, reflecting the impact of his research on the broader scientific landscape.

LEGACY AND FUTURE CONTRIBUTIONS

As a Ph.D. graduate in Biotechnology with a focus on cancer biology, Manojkumar aspires to leave a lasting legacy through his research contributions. His dedication to life sciences and commitment to ongoing projects suggest a promising future where he continues to make meaningful contributions to the scientific understanding of cancer and related fields.

NOTABLE PUBLICATIONS

Ameliorated antimicrobial, antioxidant, and anticancer properties by Plectranthus vettiveroides root extract-mediated green synthesis of chitosan nanoparticles.2023

Ameliorative Effect of Rutin against Zirconium Oxide (ZrO2) Nanoparticle induced Behavioural, Biochemical and Tissue Morphological Changes in Danio rerio.2023

 

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Myocardial recovery after percutaneous coronary intervention in coronary artery disease patients with impaired systolic function- predictive utility of global longitudinal strain.2022

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcome– A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023

 

Ms Menekse Turna – Radiation Oncology – Best Researcher Award

Posted on by Pencis

Ms Menekse Turna - Radiation Oncology - Best Researcher Award

Anadolu Medical Center - Turkey

AUTHOR PROFILE

Orchid

Scopus

Early Academic Pursuits

Menekşe Turna began her academic journey with a strong foundation at the Karadeniz Technical University Faculty Of Medicine in Trabzon, Turkey, where she dedicated six years of study from 2005 to 2011. This period laid the groundwork for her future contributions in the field of medicine.

Professional Endeavors

Upon completing her medical education, Menekşe Turna delved into the specialized field of Radiation Oncology. She started her professional journey at Okmeydani Research and Training Hospital in Istanbul, where she gained valuable experience from 2012 to 2016. Later, she expanded her horizons by joining the St James Institute of Oncology in Leeds, England, as a Clinical Observer in 2015-2016, further enriching her knowledge in the international medical landscape.

Contributions and Research Focus on Radiation oncology

Menekşe Turna's primary focus in Radiation Oncology showcases her commitment to advancing cancer treatment. Her contributions to the field involve a keen interest in therapeutic radiology, emphasizing precision and efficacy in cancer treatment methods. Through her work, she aims to contribute to the ongoing advancements in radiation therapy for improved patient outcomes.

Academic Cites

Menekşe Turna's academic achievements are reflected in her successful completion of the Second degree in the Board Exam of the Turkish Society for Radiation Oncology in 2016. This recognition signifies her expertise and proficiency in the field.

Legacy and Future Contributions

As a dedicated medical professional, Menekşe Turna is already leaving a positive mark on the field of Radiation Oncology. Her legacy lies in the lives she impacts through precise and compassionate cancer care. Looking forward, she envisions continued contributions to research, education, and patient care, leaving an enduring legacy in the medical community.

NOTABLE PUBLICATIONS

Stereotactic radiosurgery in brain metastasis: treatment outcomes and patterns of failure.2023

Evaluation of clinically involved lymph nodes with deformable registration in breast cancer radiotherapy.2022

Stereotactic body radiotherapy as a boost after external beam radiotherapy for high-risk prostate cancer patients.2021

 

Prof Dr.Jean-Pierre Gillet – Cancer Cell Biology – Best Researcher Award

Posted on by Pencis

Prof Dr.Jean-Pierre Gillet - Cancer Cell Biology - Best Researcher Award

University of Namur - Belgium

AUTHOR PROFILE

Scopus

Google Scholar

Early Academic Pursuits:

Jean-Pierre GILLET, a renowned Full Professor with a PhD in Cellular and Molecular Biology, commenced his academic journey with a Licentiate Degree in Biochemistry and Molecular and Cell Biology from the University of Namur, Belgium. He further pursued a PhD at the same institution, specializing in Cell Biology under the guidance of Professor J. Remacle.

Professional Endeavors:

Throughout his distinguished career, Jean-Pierre GILLET has held various significant positions. Notable milestones include his roles as a Staff Scientist at NIH-NCI (Bethesda, Maryland, USA) and his contributions as a Director of the Biomedical Sciences Department at the University of Namur. His extensive experience also includes being a Non-Clinical Expert for the Federal Agency for Medicines and Health Products and the European Medicines Agency.

Contributions and Research Focus on Cancer cell biology

Jean-Pierre GILLET has made substantial contributions to the field of Cancer cell Biology. His research activities encompass the molecular and functional characterization of ATP-Binding Cassette transporters, advancing esophageal adenocarcinoma treatment, and exploring olfactory receptors as a novel strategy in hepatocellular carcinoma treatment.

Impact and Influence:

Professor GILLET's impact extends beyond his research, as evidenced by his leadership roles and editorial activities. He has served on the editorial boards of prestigious journals, including "Drug Resistance Updates" and "Cancer Drug Resistance." His expertise as a reviewer for various reputable journals demonstrates his influence in shaping scientific discourse.

Academic Cites:

Jean-Pierre GILLET's academic contributions have been acknowledged through numerous awards and grants. He has received the Federal Technology Transfer Award, Merit Bonus Cash Award, NCI Director’s Intramural Career Development Innovation Award, and other recognitions for his outstanding work.

Legacy and Future Contributions:

Professor GILLET's legacy is marked by his role as the Head of the Laboratory of Molecular Cancer Biology and Director of the Biomedical Sciences Department at the University of Namur. His continued involvement in scientific societies, editorial boards, and research projects reflects his commitment to advancing knowledge and fostering future contributions.

NOTABLE PUBLICATIONS

Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes . 2004

Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis . 2009

Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions.2011

Assoc Prof Dr.Marwa Muhammad Abu-Serie Ali – Targeted Cancer Therapy – Best Researcher Award

Posted on by Pencis

Assoc Prof Dr.Marwa Muhammad Abu-Serie Ali - Targeted Cancer Therapy - Best Researcher Award

SRTA city - Egypt

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS:

Marwa Muhammad Abu-Serie Ali initiated her academic journey in the field of biochemistry, obtaining a Bachelor's degree from Alexandria University, Egypt, with honors. She continued her academic pursuits with a Master's degree in Biochemistry from the same university in 2008. Later, in 2014, Marwa achieved a significant milestone by completing her Ph.D. in the Biochemistry Department at the Faculty of Science, Alexandria University, Egypt. Her doctoral thesis focused on a model for drug assessment of colon cancer induced in murine cells.

PROFESSIONAL ENDEAVORS:

Marwa's professional journey encompasses various roles, starting from a Delegated Demonstrator at Alexandria University to her current position as an Associate Professor in the Medical Biotechnology Department at the Genetic Engineering and Biotechnology Research Institute (GEBRI) in Egypt. She has consistently contributed to research and academia, progressing from Assistant Researcher to Researcher and eventually to her current leadership position as an Associate Professor.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Marwa's research focus is on medical biotechnology, with specific interests in tageted cancer therapy studies. Her work includes projects such as the assessment of nanotherapeutic approaches in colon cancer, the development of anti-coronavirus agents, and the evaluation of novel anticancer agents. She has also explored the anti-tumor efficacy of various formulations against different types of carcinoma, emphasizing a comprehensive and innovative approach to cancer treatment.

IMPACT AND INFLUENCE:

Marwa has made significant contributions to the scientific community through her involvement in research projects funded by prestigious organizations like the Science & Technology Development Fund (STDF), Fulbright, and the Academy of Scientific Research and Technology Center (STC). Her work has not only expanded scientific knowledge but has also paved the way for potential breakthroughs in cancer treatment and the fight against infectious diseases.

ACADEMIC CITATIONS:

Marwa's academic work has likely garnered citations in various research publications, reflecting the impact of her contributions to the field of medical biotechnology. These citations signify the acknowledgment and recognition of her research by peers and fellow scientists.

LEGACY AND FUTURE CONTRIBUTIONS:

Marwa's legacy lies in her commitment to advancing knowledge in medical biotechnology, particularly in cancer research and antiviral drug development. Her future contributions are anticipated to further shape the landscape of biomedical research, potentially leading to breakthroughs in cancer treatment and viral therapeutics.

NOTABLE PUBLICATIONS

Anticancer activity of lactoferrin-coated biosynthesized selenium nanoparticles for combating different human cancer cells via mediating apoptotic effects.2023

Inhibitory effect of lactoferrin-coated zinc nanoparticles on SARS-CoV-2 replication and entry along with improvement of lung fibrosis induced in adult male albino rats.2023

Concurrent Tissue Engineering for Wound Healing in Diabetic Rats Utilizing Dual Actions of Green Synthesized CuO NPs Prepared from Two Plants Grown in Egypt.2023

 

Prof Dr.Gilles PERNOD – Cardiovascular Oncology – Best Researcher Award

Posted on by Pencis

Prof Dr.Gilles PERNOD - Cardiovascular Oncology - Best Researcher Award

CHU Grenoble-Alpes - France

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Gilles PERNOD embarked on his academic journey with a strong foundation, earning his A-levels in Mathematics in 1979. His dedication and early academic achievements laid the groundwork for a distinguished career in the field of medicine.

PROFESSIONAL ENDEAVORS

Gilles PERNOD's professional journey officially began with the completion of his degree in Medicine in 1985, marking the commencement of his commitment to the medical field.Driven by a thirst for knowledge, PERNOD furthered his academic pursuits, achieving a Doctorate in Medicine in 1991. This academic milestone showcased his dedication to advancing medical understanding. PERNOD's expertise expanded into the realm of Haematology in 1998 when he assumed the role of Assistant Professor, contributing significantly to the medical education landscape.Recognizing his exemplary contributions, PERNOD attained the prestigious title of Professor of University in Vascular Medicine in 2007, a testament to his expertise and leadership in the field.

CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR ONCOLOGY

Throughout his career, PERNOD has been instrumental in advancing vascular medicine and haematology. As the Head of the Vascular Medicine Unit since 2018 at CHU Grenoble-Alpes, he continues to lead groundbreaking research initiatives. PERNOD's leadership of the ThEMAS TIMC IMAGUMR CNRS 5525 research group highlights his commitment to collaborative and innovative research, contributing to the collective understanding of thrombo-embolic diseases.His involvement in the INNOVTE Network emphasizes PERNOD's dedication to enhancing thrombo-embolic disease diagnostics and clinical research on an international scale.

IMPACT AND INFLUENCE

Gilles PERNOD's influence extends globally through active participation in international societies and professional associations. Membership in the International Society of Thrombosis and Haemostasis showcases his commitment to staying at the forefront of advancements in his field.

ACADEMIC CITES

As a Professor of University, PERNOD's academic contributions are evidenced by his Qualification to Direct Student Research in 2004. This recognition underscores the impact of his research and mentorship on the next generation of medical professionals.

LEGACY AND FUTURE CONTRIBUTIONS

Gilles PERNOD's legacy is marked by his significant contributions to vascular medicine, cardiovascular oncology and haematology. His commitment to ongoing research, coupled with leadership roles, positions him to continue shaping the future landscape of these fields. His influence on perioperative hemostasis and commitment to medical education underscore his dedication to advancing medical knowledge.

NOTABLE PUBLICATIONS

Management of venous thromboembolic disease in patients with malignant brain tumours .2024

Cancer-related arterial thromboembolic events.2024

Update About the Management of Low-Density Lipoprotein Cholesterol and Hypertriglyceridemia in Lower Extremity Peripheral Artery Disease Patients: Consensus of the French Society of Vascular Medicine and the French Society for Vascular and Endovascular Surgery.2023

Mr.Eric Naab Manson – Medical Physics – Best Scholar Award

Posted on by Pencis

Mr.Eric Naab Manson - Medical Physics - Best Scholar Award

University for Development Studies - Ghana

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Commencing with the Senior Secondary School Certificate Examination at Kanton Senior Secondary School from 2001 to 2003, Eric laid the foundation for his academic journey.

PROFESSIONAL ENDEAVORS:

Eric's career spans diverse roles, from being a Physics Tutor to an Assistant Lecturer, showcasing his commitment to both education and the advancement of medical physics.

CONTRIBUTIONS AND RESEARCH FOCUS ON MEDICAL PHYSICS

Dedicated to medical imaging and cancer research, Eric actively contributes to advancing diagnostics and treatments. His engagement with research groups emphasizes collaboration for groundbreaking discoveries.

IMPACT AND INFLUENCE:

Through teaching roles and ongoing research, Eric has the potential to influence academic and practical aspects of medical physics, leaving a lasting impact on students and the field.

ACADEMIC CITES:

Eric's pursuit of a Ph.D. in Medical Physics at the University of Ghana suggests an ongoing and impactful academic journey.

LEGACY AND FUTURE CONTRIBUTIONS:

Eric's legacy lies in his dedication to medical physics education and research. As he continues his Ph.D., his future contributions are expected to enrich the field, with a collaborative and exploratory approach indicating sustained impact.

NOTABLE PUBLICATIONS

Fighting breast cancer in low-and-middle-income countries – What must we do to get every woman screened on regular basis?2023

Evaluation of the impact of magnetic field homogeneity on image quality in magnetic resonance imaging: a baseline quantitative study at 1.5 T.  2023

Dr. Siim Pauklin – Targeted Cancer Therapy – Best Researcher Award

Posted on by Pencis

 

Dr. Siim Pauklin - Targeted Cancer Therapy - Best Researcher Award

University of Oxford - United Kingdom

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Siim Pauklin embarked on his academic journey with a Bachelor's degree in Molecular and Cell Biology from the University of Tartu in Estonia, earning the distinction of Diploma Cum Laude in 2004. He further pursued his academic interests with a Master's degree in Molecular and Cell Biology at the same institution, completing it with distinction in 2005. His early academic pursuits showcased exceptional dedication and achievement in the field.

PROFESSIONAL ENDEAVORS:

Following his Master's degree, Siim Pauklin expanded his academic horizons with a Ph.D. in Biochemistry and Molecular Biology at University College London / CRUK London Research Institute from September 2005 to October 2009. His Ph.D. research, titled "Regulation of Activation Induced Deaminase (AID)," not only earned him the prestigious Pontecorvo prize for the best thesis in CRUK but also led to groundbreaking discoveries in the regulation of AID expression by hormones and its role in immune responses, autoimmune diseases, and tumorigenesis.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Siim Pauklin's research has been instrumental in advancing our understanding of stem cell biology and cancer research, particularly in the molecular mechanisms regulating cancer stem cell formation. His work on the TGFß/Activin/Nodal-SMAD2/3 signaling pathway in pancreatic ductal adenocarcinomas and cancer stem cells has paved the way for insights into chemoresistance, metastatic capacity, and the 3D chromatin architecture of pancreatic cancer.

IMPACT AND INFLUENCE:

Siim Pauklin's impact in the field is evident from his career trajectory, securing prestigious fellowships, awards, and recognition for his significant contributions. His leadership as a Principal Investigator and CRUK Career Development Fellow at the University of Oxford underscores his influence in the scientific community.

LEGACY AND FUTURE CONTRIBUTIONS:

Siim Pauklin's research focus on Targeted cancer therapy and pancreatic cancer. As he continues to lead his research group at the University of Oxford, his commitment to uncovering early detection methods and advancing therapeutic strategies for cancer stem cells promises a lasting impact on the field. His future contributions are anticipated to further shape our understanding of cancer biology and contribute to the development of novel cancer therapies.

NOTABLE PUBLICATIONS

BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma. 2023

KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics. 2023

Epigenetic and transcriptional regulations prime cell fate before division during human pluripotent stem cell differentiation.2023